Nuvectis Pharma, Inc.
corporate_fare Company Profile
Nuvectis Pharma, Inc. (NASDAQ:NVCT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for NVCT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-24, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for NVCT spans S-3, 10-Q, 8-K, 4.
Recent high-impact activity:
- NXP200 Wins Breakthrough Therapy Designation in China for High-Grade Glioma
- Nuvectis Files $200M Shelf and $75M ATM, Replacing Prior Programs
- Nuvectis Q2: $115M Raise Closes, Haisco Deal Activated, NXP100 Approved in China
- Nuvectis Q2 2026: $115M Offering Closes, Ciprocopan Approved in China
- Nuvectis Posts Q2 Loss, But $115M Raise and Ciprocopan Approval in China Fuel Pipeline Push
Financial Snapshot
Short Interest & Short Volume
14.77 days to coverFINRA reported short interest of 2,362,527 shares in NVCT as of the September 15, 2026 settlement, a 7.6% increase from the prior period — about 14.8 days to cover at its recent average daily volume. On October 2, 2026, 82.7% of NVCT volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for NVCT, detected from its recent SEC filings · based on capital-structure filings through 2026-08-21.
Public Offering Priced · Significant Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →